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cRel expression regulates distinct transcriptional
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Abstract
Objectives. NF-jB regulates genes that control inflammation, cell proliferation, differentiation and survival.
Dysregulated NF-jB signalling alters normal skin physiology and deletion of cRel limits bleomycin-induced skin
fibrosis. This study investigates the role of cRel in modulating fibroblast phenotype in the context of SSc.
Methods. Fibrosis was assessed histologically in mice challenged with bleomycin to induce lung or skin fibrosis.
RNA sequencing and pathway analysis was performed on wild type and Rel/ murine lung and dermal fibroblasts.
Functional assays examined fibroblast proliferation, migration and matrix production. cRel overexpression was
investigated in human dermal fibroblasts. cRel immunostaining was performed on lung and skin tissue sections
from SSc patients and non-fibrotic controls.
Results. cRel expression was elevated in murine lung and skin fibrosis models. Rel/ mice were protected from
developing pulmonary fibrosis. Soluble collagen production was significantly decreased in fibroblasts lacking cRel
while proliferation and migration of these cells was significantly increased. cRel regulates genes involved in extra-
cellular structure and matrix organization. Positive cRel staining was observed in fibroblasts in human SSc skin and
lung tissue. Overexpression of constitutively active cRel in human dermal fibroblasts increased expression of matrix
genes. An NF-jB gene signature was identified in diffuse SSc skin and nuclear cRel expression was elevated in
SSc skin fibroblasts.
Conclusion. cRel regulates a pro-fibrogenic transcriptional programme in fibroblasts that may contribute to dis-
ease pathology. Targeting cRel signalling in fibroblasts of SSc patients could provide a novel therapeutic avenue to
limit scar formation in this disease.
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Introduction
SSc is characterized by activation and accumulation of
fibroblasts in multiple organs. SSc fibroblasts secrete
elevated levels of extracellular matrix (ECM) compo-
nents: collagens, glycosaminoglycans and fibronectin,
which promote scar formation and dermal thickening
[1–3]. Fibroblast activation and differentiation into an
alpha-smooth muscle actin (aSMA)-positive myofibro-
blast is associated with increased proliferation, aber-
rant secretion of ECM proteins and inflammatory
chemokines [4, 5]. Phenotypic activation of fibroblasts
is mediated by multiple stimuli, including TGF-b, ECM-
degrading proteases and inflammation [6, 7]. Canonical
NF-jB signalling promotes fibroblast survival in the liver
[8, 9], heart [10] and kidney via cell cycle regulation,
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anti-apoptotic pathway activation and modulating ma-
trix turnover [11, 12].
The NF-jB transcription factor family is composed
of five members: p50 (NF-jB1), p52 (NF-jB2), RelA
(p65), RelB and cRel. Subunits exist as either homo-
dimers or heterodimers in various permutations and
are sequestered in an inactive form within the cyto-
plasm by IjBa. Classically, pro-inflammatory insult or
damage stimuli activate the IjB kinase (IKK) complex
resulting in IjBa phosphorylation, targeting it for pro-
teasomal degradation thus allowing NF-jB dimers to
enter the nucleus and drive target gene transcription
[13]. NF-jB signalling plays an essential role in main-
taining normal skin physiology, IjBa null mice die of
reduced skin barrier function, whilst IKK1 knockout
mice are viable but have skin defects [14]. Aberrant
NF-jB activation has been implicated in the develop-
ment of chronic skin diseases; transgenic mice over-
expressing active p50 or RelA in skin cells develop
epidermal hypoplasia and die prematurely [15]. In SSc
patients, a genome-wide association study identified
an intronic polymorphism in the NFKB1 gene encoding
p105/p50 as a risk factor for SSc [16]. The link be-
tween NF-jB signalling and SSc was further consoli-
dated in separate studies that reporting chemical
inhibition of NF-jB or small interfering RNA-targeting
of RelA in normal and SSc fibroblasts determined the
extent of collagen synthesis [17, 18]. Bioinformatic
analysis of tissue-specific cellular modulators of fibro-
sis has also implicated NF-jB signalling and function-
ality in both skin and lung fibrosis in SSc patients
[19]. Furthermore, risk loci in the REL gene have been
identified in psoriasis and PsA [20, 21].
A role for cRel-dependent signalling in epidermal dis-
orders has been described in animal models [22–24].
Epidermal thickness is reduced in cRel global knockout
mice, and these mice develop less skin fibrosis in re-
sponse to chronic bleomycin injury [23, 25]. Additionally,
a pro-fibrogenic role for cRel has been identified in mur-
ine models of cardiac and liver fibrosis, suggesting that
cRel regulates fibrogenic processes in multiple organs
[26, 27].
This study employs both non-biased transcriptomic
and targeted functional approaches to discern the role
of cRel in modulating the phenotypic traits of lung
and skin fibroblasts. We report that cRel controls the
expression of a distinct subset of matrix genes that
are elevated in SSc and propose that targeting cRel
in SSc patients may lead to novel anti-fibrotic
therapies.
Methods
An extended Methods section is available in the supple-
mentary material, section Methods, available at
Rheumatology online.
Animal experiments were approved following local
ethical review and performed under a UK Home Office
license. Human foreskin and SSc forearm skin samples
were taken under full ethical approval and with patient
consent (Dermatology biobank ethics Ref: 08/H0906/95)
sponsored by the Newcastle upon Tyne Hospitals
Foundation Trust (R&D biobank reference: 4775) and the
University of Manchester (Scleroderma and Raynaud’s
Research Bank REC14/NW/0132) and Sunderland
Research Ethics Service (REC approval reference 13/
NE/0089). Human lung samples were taken under full
ethical approval and patient consent (REC approval ref-
erence 11/NE/0291). All SSc patients fulfilled the new
ACR/EULAR criteria for SSc [28]. Patient characteristics
of the skin biopsy cohort are included in supplementary
Table S1, available at Rheumatology online.
Animal studies
Wild-type (WT) and Rel/ mice on a pure C57BL/6
background were from Jorge Caamano (Birmingham
University, Birmingham, UK). Adult male mice aged
8–10 weeks old, were used for experimental models.
Samples from TSK1 (The Jackson Laboratory: B6.Cg-
Fbn1Tsk þ/þ Bloc1s6pa/J Stock No.: 000305) mice and
pa/pa mice were from Oliver Distler (University Hospital
Zurich, Zurich, Switzerland). Bleomycin-induced dermal
fibrosis by s.c. injection for 4 weeks and lung fibrosis by
single intra-tracheal instillation was carried out as previ-
ously described [23, 29]. S.c. injections or intra-tracheal
instillations of 0.9% saline served as a vehicle control.
All studies were performed with full ethical approval and
under a UK home office licence.
Cell culture
Dermal fibroblasts from healthy control samples were
cultured as previously described [30]. Fibroblasts were
isolated from skin biopsies of clinically affected forearm
of patients with SSc [31]. Fibroblasts were transfected
using Effectene (Qiagen, Manchester, UK) according to
standard protocols.
RNA sequencing
RNA was extracted from mouse skin and lung fibroblasts
using RNeasy Plus Micro Kit (Qiagen, Manchester, UK).
Rheumatology key messages
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After checking RNA integrity, mRNA was purified and libra-
ries were prepared using NEB Next Ultra Directional RNA
Library Prep Kit for Illumina (NEB, Hitchin, UK). The libraries
were sequenced on an Illumina HiSeq 2000 and quality
control was carried out with FASTQC (www.bioinformatics.
babraham.ac.uk/projects/fastqc). All of our original se-
quence data have been deposited in (the GEO data reposi-
tory; GSE151469). Reads were aligned to the mouse
genome and quantified with STAR (doi: 10.1093/bioinfor-
matics/bts635) in two-pass mode, and further sample qual-
ity control and differential expression analysis were
performed in R with DESeq2 (doi: 10.1186/s13059-014-
0550-8).
Plasmids transient transfection
For transient transfection, human dermal fibroblasts cells
were seeded in six-well plates at 2 105 cells per well.
The cells were then transfected for 48 h with 1.0mg
human FLAG-tagged DRIDcRel (Addgene #27265,
Teddington, UK) and human Hemagglutinin (HA)-tagged
RelA (gift from Neil Perkins). The empty pcDNA3 vector
was used as a mock transfection control. Transfection
was performed using Effectene reagent according to the
instructions specified by the manufacturer (Qiagen,
Manchester, UK).
Immunofluorescence
Fibroblasts were seeded at 12.5 104 cells per well in an
eight-well chamber slide. Cells were fixed in 3.7% formal-
dehyde (Sigma), permeabilized in 0.1% Triton-X100 and
blocked by incubation in 1% BSA (Sigma, Dorest, UK).
They were then incubated overnight at 4C, with an anti-
cRel (Santa Cruz sc-70, Heidelberg, Germany) followed
by incubation with goat-anti rabbit secondary antibody
(Invitrogen A-11035). Nuclei were counterstained with
DAPI (Invitrogen, Paisley, UK) and images obtained using
a Nikon Inverted Confocal Microscope.
Histology and immunohistochemistry
Deparaffinized and rehydrated sections were incubated
in 2% hydrogen peroxide/methanol for 15 min. aSMA
staining was performed as described previously [32].
Tris-EDTA antigen retrieval (pH 9) was performed at
95C for 20 min. Sections were blocked with an avidin/
biotin kit (SP-2001; Vector Laboratories, Burlingame,
CA, USA) for 20 min, then with 20% pig serum in PBS
for 20 min. Slides were incubated overnight at 4C with
rabbit primary antibodies directed against cRel diluted
1:150 (Abcam ab108299, Cambridge, UK) in PBS. Slides
were washed with PBS and then incubated with biotiny-
lated swine anti-rabbit (E0353; Dako, Glostrup,
Denmark) for 1.5 h. Amplification of antigen was
achieved using an R.T.U. Vectastain kit (Vector
Laboratories), and positive cells were visualized by 3,3-
diaminobenzidine tetrahydrochloride. Masson’s
Trichrome staining was performed as previously
described [33]. All tissue sections were analysed at
200 magnification using a Nikon Eclipse Upright
microscope and percentage area of positive stained tis-
sue was quantified using NIS-Elements BR analysis
software.
Scoring of clinical samples
Semi-quantitative analysis (by blinded observer) of cRel
staining was performed using a scoring system based
on the number of fibroblasts that were positively stained
in both the papillary and reticular dermis (0–3) in both
anatomical layers. No staining scored 0, 0–40% scored
1, >40–60% scored 2 and >60% scored 3.
Statistical analysis
Data were analysed using GraphPad Prism version 5.01
for Windows (GraphPad, San Diego, CA, USA). For two-
group comparisons, Student’s t-test was applied if the
pre-test for normality (D’Agostino-Pearson normality-
test) was not rejected at 0.05 significance, in which case
a Mann–Whitney U test for non-parametric data was
used. P-values <0.05 were considered significant.
Results
cRel is a pro-fibrogenic driver of matrix production
in chronic fibrosis models
Immunohistochemistry confirmed cRel expression was
elevated in the skin and lung after bleomycin challenge.
Nuclear localization of cRel was observed in the epider-
mis and dermal fibroblasts of fibrotic skin, whereas cRel
was visible in fibroblasts, epithelial cells and alveolar
macrophages of the lung (Fig. 1A and B). We previously
reported that cRel knockout (Rel/) mice are protected
from developing dermal fibrosis [23]; however, the role
of cRel in lung fibrosis had not previously been
explored. Intra-tracheal bleomycin challenge is associ-
ated with severe acute lung injury followed by inflamma-
tion and fibrosis [34]. Bleomycin elicited the expected
structural changes, accumulation of collagen and activa-
tion of aSMAþ myofibroblasts in the lungs of WT mice
(Fig. 1C and D). Conversely, fibrosis and myofibroblast
activation were significantly attenuated in Rel/ mice
after bleomycin challenge (Fig. 1C and D). Histological
improvement in fibrosis was accompanied by a signifi-
cant reduction in fibrogenic gene expression and
hydroxyproline levels (supplementary Fig. S1A and B,
available at Rheumatology online). These data highlight
a pro-fibrogenic role of cRel in the pathogenesis of
chronic lung fibrosis.
cRel regulates a distinct transcriptional profile in
lung and skin fibroblasts
To test if cRel signalling modulates fibroblast phenotype
we performed RNA-sequencing on un-passaged WT
and Rel/ lung and skin fibroblasts. cRel deletion in
fibroblasts was confirmed by western blot (supplemen-
tary Fig. S2A, available at Rheumatology online). A total
of 19 genes were differentially expressed (DE) in Rel/
cRel in modulating fibroblast phenotype in the context of SSc
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compared with WT lung fibroblasts (Fig. 2A), while 181
genes were DE in Rel/ compared with WT skin fibro-
blasts (Fig. 2B). Significantly down-regulated genes in
Rel/ lung fibroblasts included key regulators of ECM:
collagens Col4a1, Col5a2, Col11a1, Col18a1, MMP 3
(Mmp3) and Tenascin C (Tnc) (Fig. 2A). Similarly, down-
regulated genes in Rel/ skin fibroblasts included ECM
components/regulators: Col4a1, Col5a2, fibronectin
(Fn1), plexin D1 (Plxd1) and fibrillin-1 (Fbn1) (Fig. 2B).
Validation of RNA-sequencing data was performed using
qPCR (Fig. 2C and supplementary Fig. S2B and C, avail-
able at Rheumatology online). Col4a1 and Col5a2 were
the only DE genes conserved between lung and skin
fibroblasts. Expression of known drivers of fibrosis Fn1
and Tnc were significantly down-regulated in Rel/ skin
and lung fibroblasts respectively (Fig. 2C).
cRel chromatin immunoprecipitation assays were per-
formed on WT lung and skin fibroblasts. Binding was
FIG. 1 cRel in chronic models of skin and lung fibrosis
(A and B) Quantification and representative images of cRel staining in the skin (A) and lung (B) of saline control and
bleomycin-injured mice (n ¼ 6 mice/group). Arrows indicative of cRel nuclear positivity, SM denotes smooth muscle
and HF highlights hair follicle. (C and D) Histological quantification and representative images of (C) Masson’s
Trichrome and (D) a-smooth muscle actin (aSMA) staining in 21-day bleomycin-injured lungs from wild type (WT) and
Rel/ mice. Red line on graph denotes levels in control saline treated animals. (C) Images were taken at 200 mag-
nification, scale bars equal 100 mm. Data are presented as percentage stained area of tissue sections (n ¼ 12) for WT
and (n ¼ 9) for Rel/ mice. Data are presented as mean (S.E.M.). *P < 0.05, **P < 0.01; statistical analysis performed
using Mann–Whitney U test.
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FIG. 2 cRel deletion in lung and skin fibroblasts alters matrix gene expression
(A and B) Heat map of differentially expressed (DE) genes in un-passaged wild type (WT) versus Rel/ (A) lung and
(B) skin fibroblasts (P < 0.05). Expression across each gene (or row) scaled so that mean expression is zero and S.D.
is one. Samples with relatively high expression of a given gene are marked in red and samples with relatively low ex-
pression are marked in blue. Hierarchical clustering has reordered samples and genes. Dendrogram shows sample
clustering. (C) qPCR validation of matrix gene expression in lung and skin fibroblasts Col4a1, Col5a2, Fn1 and Tnc.
Data are presented as mean (S.E.M.). *P < 0.05, **P < 0.01 by Mann–Whitney U test (n ¼ 6 per group). (D) Conserved
gene ontology (GO) classifications that are significantly enriched in both lung (black bars) and skin fibroblasts (clear
bars) (P < 0.05). (D) Ingenuity Pathways Analysis (IPA) Diseases and Functions Annotation for skin fibroblasts (func-
tionally different clusters with lowest P-values and highest z-scores).
cRel in modulating fibroblast phenotype in the context of SSc
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significantly enriched at Col1a1, Col4a1 and Fn1 pro-
moters in lung fibroblasts (supplementary Fig. S2D, avail-
able at Rheumatology online). Consistent with the
cultured fibroblast RNA sequencing data, a significant de-
crease in expression of matrix genes Col4a1, Fn1, Tnc
was observed in the skin of bleomycin injured Rel/ mice
(supplementary Fig. S2E, available at Rheumatology
online).DE genes identified in murine skin fibroblasts were
compared with four publicly available SSc patient tran-
scriptomic microarray datasets. Overlap of DE genes with
three disease subsets: diffuse, limited and morphea (sup-
plementary Fig. S2F, available at Rheumatology online),
FN1 was elevated in all disease subsets, COL5A2 (limited
and morphea), while COL4A1 was elevated in diffuse dis-
ease. The IKBKB gene, which encodes IKKb, an NF-jB
activating kinase, was significantly elevated in diffuse dis-
ease and identified as an upstream regulator of cRel-
dependent genes in skin fibroblasts (supplementary Table
S2, available at Rheumatology online).
To investigate the functional relevance of cRel signal-
ling in fibroblasts, we performed Gene Ontology (GO)
analysis of DE genes identified in both skin and lung
data sets. GO analysis revealed significant enrichment
for terms such as supramolecular fibre organization,
ECM structure and organization, all of which belong to
the cellular component ontology (Fig. 2D). Further inter-
rogation of shared cellular component GO terms identi-
fied enrichment in ECM components, collagen trimers,
fibrils and basement membrane (supplementary Fig.
S3A, available at Rheumatology online). Ingenuity
Pathway Analysis was used to identify predicted dis-
eases and functions associated with DE genes in Rel/
skin fibroblasts. Up-regulated functions included cellular
growth, movement and proliferation, whereas dermato-
logical diseases and conditions are reduced in Rel/
fibroblasts (Fig. 2E). Upstream canonical pathways
associated with fibrosis were also activated (supplemen-
tary Fig. S3B, available at Rheumatology online).
In a non-inflammatory fibrosis model; the tight skin
mouse (TSK1), cRel expression was elevated and local-
ized to regions of dense fibril formation (supplementary
Fig. S4A, available at Rheumatology online), accompa-
nied by significantly increased cRel and matrix gene ex-
pression (supplementary Fig. S4B, available at
Rheumatology online).
cRel null fibroblasts have distinct functional
capabilities
Matrix production and secretion, assessed by the Sircol
assay, was significantly lower in the cellular superna-
tants of both Rel/ lung and skin fibroblasts (Fig. 3A
and B). Whilst 50-bromo-20-deoxyuridine (BrdU) assay
and scratch assays confirmed Rel/ lung and skin
fibroblasts display increased proliferation and migration
rates compared with their WT counterparts (Fig. 3C–F).
Significant increases in wound closure were observed
as early as 6 h in Rel/ lung fibroblasts, whereas in
Rel/ skin fibroblasts accelerated migration was evi-
dent from 24 h (Fig. 3E and F). One hundred percent
wound closure was observed at 48 h in Rel/ fibro-
blasts, compared with WT fibroblasts with only 50%
wound closure at the same timepoint. These functional
observations were also validated in 3D spheroids (sup-
plementary Fig. S5A–E, available at Rheumatology on-
line). These findings illustrate the biological effects of
cRel signalling in fibroblasts are to increase the fibro-
genic potential and suppress the migratory and prolif-
erative phenotype.
Constitutively active cRel drives expression of
matrix genes in human dermal fibroblasts and cRel
activity is increased in SSc dermal fibroblasts
We next asked if cRel regulates matrix production in
human dermal fibroblasts. Immunofluorescence staining
revealed cRel (red) expression is relatively low in normal
human dermal fibroblasts (NHDF) but markedly elevated
in SSc fibroblasts. Localization of cRel in SSc fibroblasts
was both nuclear (arrows) and cytoplasmic, suggesting
that under disease conditions, cRel is active, whereas
cRel in NHDF is predominantly inactive and confined to
the cytoplasm (Fig. 4A). These data indicate that during
disease, cRel signalling becomes persistently activated.
To model this in vitro, plasmid constructs containing a
constitutively active cRel (cRelDRID) were transiently
transfected into NHDF and matrix gene expression was
assessed. cRel overexpression was confirmed by qPCR
(supplementary Fig. S6A, available at Rheumatology on-
line) and western blot (FLAG-tag) (supplementary Fig.
S6B, available at Rheumatology online). cRelDRID sig-
nificantly increased COL4A1, COL5A2, TNC and FN1
gene expression (Fig. 4B) and soluble collagen produc-
tion (Fig. 4C) compared with empty vector controls.
There was no difference in expression of these genes or
in soluble collagen production when the RelA was over-
expressed. These data confirm that in human dermal
fibroblasts cRel regulates a subset of matrix genes and
collagen production.
Normal and SSc fibroblast gene expression was com-
pared and consistent with a highly activated phenotype
(supplementary Fig. S6C, available at Rheumatology on-
line). Genes identified to be regulated by cRel in this
study including TNC and FN1 were also significantly
increased in SSc fibroblasts, although COL4A1 and
COL5A2 gene expression were elevated but did not
reach significance (Fig. 4D).
cRel expression is elevated in fibroblasts of SSc
skin and lung
We examined cRel expression and cellular localization in
the skin of 8 non-fibrotic controls and 20 SSc patients,
with either dcSSc or lcSSc. cRel expression was mark-
edly increased in SSc skin compared with control, non-
fibrotic skin. Consistent with our previous study [23], the
epidermis of non-fibrotic skin showed infrequent
nuclear-positive cRel staining in keratinocytes of the
basal layer, while there was an increase in nuclear posi-
tivity of keratinocytes in the basal layer and stratum
Julie C. Worrell et al.
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spinosum in SSc skin (Fig. 5A). Semi-quantitative ana-
lysis of the cRel IHC confirmed a statistically significant
upregulation of cRel in fibroblasts of SSc skin compared
with control skin (Fig. 5B). High cRel expression was
more pronounced in fibrotic SSc patient skin, based on
histological skin score, compared with control skin.
There was a trend towards higher cRel levels in the der-
mis of dcSSc compared with lcSSc (data not shown)
but no correlation with disease duration (supplementary
Table S1, available at Rheumatology online). Expression
of cRel-regulated matrix and fibrogenic genes was eval-
uated in a small cohort of non-fibrotic and SSc skin.
REL, aSMA, COL5A2, FN1 and TNC gene expression
was increased in all three SSc donors compared with
control skin (Fig. 5C). Interestingly, plasma levels of FN1
were significantly higher in SSc patients compared with
healthy controls (supplementary Fig. S6D, available at
Rheumatology online).
Finally, we assessed cRel expression in sections from
non-fibrotic and SSc lungs. The expected histological
features of SSc and fibrosis were confirmed using
haematoxylin and eosin- and Masson’s Trichrome-
stained lung tissue sections (Fig. 5D). cRel levels were
elevated in SSc lung compared with non-fibrotic con-
trols, with positive staining observed in immune cells (al-
veolar macrophages and inflammatory infiltrate) and
surrounding vessels. All SSc patients had numerous
fibroblastic foci visible within the lung accompanied by
FIG. 3 cRel knockout fibroblasts have distinct functional capabilities
Fibroblasts isolated from WT and Rel–/– lung and skin. (A and B) Sircol Assay measuring soluble collagen production
(lg/ml); (C and D) 50-bromo-20-deoxyuridine (BrdU) assay measuring cellular proliferation, (E and F) scratch assay
measuring cellular migration over time. Assays were performed at 24 h post-plating unless otherwise stated.
Experiments performed on fibroblasts at passage 1–4. Data are presented as mean (S.E.M.) and are representative of
at least three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 by Mann–Whitney U test.
cRel in modulating fibroblast phenotype in the context of SSc
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dense bundles of ECM. Fibroblasts located within
the fibroblastic foci stained positively for cRel (Fig. 5D).
SSc lung pathology and localization of cRel staining was
consistent between the three SSc donors (supplementary
Fig. S7, available at Rheumatology online). Localization of
cRel in fibrotic areas and SSc lung fibroblasts further high-
light the relevance of this NF-jB subunit in dcSSc.
Discussion
This study provides multiple lines of evidence that cRel
expression is elevated in fibrotic skin and lung, in both
murine fibrosis models and human disease. In cultured
murine and human fibroblasts, cRel regulates fibroblast
phenotype and ECM production. Activation of canonical
NF-jB signalling has been linked with ECM production
in dermal fibroblasts [18]; however, these studies
focussed on signalling via p50 and p65 (RelA) hetero-
dimers. This is the first study to directly assess the role of
cRel in fibroblast biology and functionality. Here, we iden-
tify a distinct transcriptomic profile of cultured Rel/
fibroblasts. The fibrogenic phenotype and production of
ECM components is suppressed in Rel/ cells, favouring
a shift towards a pro-proliferative and migratory behav-
iour. Fibroblasts are a heterogeneous population of highly
plastic cells, exhibiting a spectrum of phenotypic traits
during their transition from a fibroblast to an activated
FIG. 4 cRel activity is increased in SSc dermal fibroblasts and drives the expression of matrix genes
(A) Immunofluorescence staining for cRel in NHDF and SSc fibroblasts, images taken at 200 magnification, scale
bars equal 100 lm. Arrows denote nuclear positivity. (B) Relative mRNA expression of matrix genes COL4A1,
COL5A2, FN1 and TNC in normal human dermal fibroblasts (NHDF) following transient transfection with cRel DRID,
RelA or empty plasmid for 48 h (n¼ 5 donors). (C) Sircol Assay measuring soluble collagen production (lg/ml) in
NHDF following transient transfection with cRelDRID, RelA or empty plasmid for 48 h (n¼ 5 donors). (D) Relative
mRNA levels of COL4A1, COL5A2, FN1 and TNC in NHDF (n¼ 3) and SSc fibroblasts (n¼ 4) per group. Experiments
performed on fibroblasts at passage 2–6. Data are presented as mean (S.E.M.). *P < 0.05 by Mann–Whitney U test.
Julie C. Worrell et al.
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myofibroblast during wound healing and fibrosis. Our
data implicate cRel as a key modulator of this transition.
We predicted IKBKB as an upstream regulator of cRel-
dependent gene transcription in skin fibroblasts. Previous
studies by Milano et al. identified an intrinsic SSc ‘gene
signature’ [35]; we validated IKBKB (IjBb) as a member of
the ‘diffuse-proliferative’ or ‘fibro-proliferative’ subset
using publicly available microarray data. The IKK/IKBKB/
NF-jB axis is important in other collagen induced disor-
ders, Ikkb/ mice are protected from developing CIA [36]
and IjBb loss dramatically reduces TNF-a-mediated
inflammation despite normal NF-jB activation. In human
disease, two novel single nucleotide polymorphisms map-
ping to the REL locus are associated with RA [37].
Lung involvement in SSc significantly contributes to
disease morbidity and mortality [38]. Lung and skin fibro-
blasts from scleroderma patients exhibit elevated matrix
production, increased contractility and increases in ‘acti-
vation markers’, and subtle differences have been
observed in migratory capacity on 3D substrates. It is like-
ly that in addition to regulating a core matrix function,
cRel also regulates discrete biological functions in lung
FIG. 5 cRel expression is elevated in fibroblasts of SSc skin and lung
(A) Representative images of cRel staining in non-fibrotic skin (n ¼ 8) and scleroderma (SSc) skin tissue (n ¼ 20),
showing dermal and epidermal positivity. (B) cRel staining scores illustrating the relative staining intensity of fibro-
blasts in the dermis. (C) Relative mRNA levels of aSMA, COL4A1, FN1 and REL was quantified in normal skin and
SSc skin (n ¼ 3) per group. (D) Representative images of haematoxylin and eosin (H&E), Masson’s Trichrome (MT)
and cRel staining in non-fibrotic lung (n ¼ 3) and SSc lung tissue (n ¼ 3). SM denotes smooth muscle and FF repre-
sents fibroblastic foci; arrows indicate fibroblasts. All images taken at 200 magnification and scale bars are repre-
sentative of 100 lm. Data presented as mean (S.E.M.). *P < 0.05 by Mann–Whitney U test.
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and skin. RNA-sequencing revealed that expression of
only two genes (Col4a1 and Col5a2) was conserved be-
tween fibroblasts isolated from the two organs. However,
a previous transcriptomic study reported that fibroblasts
isolated from different tissues display similar morphology
but can exhibit different functional properties, a concept
termed ‘positional memory’ [39]. Interestingly, pathways
identified in this study included ECM synthesis, cell prolif-
eration and cell migration, functional phenotypes that are
modulated by cRel in both skin and lung fibroblasts.
Therefore, despite the ability of cRel to regulate discrete
genes within anatomically distinct fibroblasts, cRel dele-
tion conveys similar functional outcomes.
Persistence of fibroblasts creates a pro-fibrotic micro-
environment and drives SSc pathogenesis. Work by Xie
et al. identified the percentage of matrix fibroblast ex-
pansion in bleomycin-induced lung fibrosis as greater
than the aSMAþ myofibroblast population, implicating
matrix-producing fibroblasts as the dominant driver of
lung fibrosis [40]. The transcriptomic profile of matrix-
producing fibroblasts in this study was consistent with
our findings; Cxcl14 was the most distinct extracellular
expressed gene, with enrichment of transcription factor
Aebp [40]. cRel could be a ‘genetic switch’ that pro-
motes the ECM-producing fibrotic fibroblast fate; a simi-
lar role has recently been identified for transcription
factor PU.1 in multiple models of lung and skin fibrosis
[41]. Functionally, Rel/ fibroblasts may be more migra-
tory/contractile due to alterations in the matrix they de-
posit or because the balance between contractile and
matrix producing fibroblasts has been altered.
Deposition and accumulation of matrix is regulated by
a network of matricellular proteins, including fibronectin
and tenascin-C. Many matricellular proteins are directly
regulated by TGF-b, altered signalling drives the produc-
tion/accumulation of matrix [42], in the context of our find-
ings it is plausible that TGF-b is a target of cRel. This
regulatory role of cRel in fibroblasts could be via modula-
tion of both fibrillogenesis and matrix organization; previ-
ous studies in TSK1 models identified Col5a2 [43] and
Tnc [44] as regulators of matrix formation and fibril forma-
tion. Alteration of Col1/ColV fibres in Rel/ mice may
render the fibres more accessible to proteolytic enzymes
or ease accessibility to MMP degradation. In human dis-
ease, elevated expression of TNC [45], FN1 [46], COL4A1
[47] and COL5A2 [48] have all been described in diffuse
SSc. TNC [49] and FN1 [50] are known NF-jB target
genes, but to our knowledge this is the first study to link
these genes to cRel-dependent signalling.
In mice treated with bleomycin, cRel induction is fol-
lowed by its persistence in lesional tissue, while Rel/
mice show reduced aSMAþ cells and less fibrosis.
Elevation and activation of cRel was observed in fibro-
blasts and skin of SSc patients, although this did not cor-
relate with disease progression. Our SSc patient study
cohort contained only three male patients, consistent with
an overall female predominance of the disease [51].
Although cRel staining was elevated in the dermis of male
(n¼3) patients, when compared with female patients
(n¼17), the sample size was too small to interpret this
further. It should also be noted that the median age of
male patients was higher than that of female patients (67
vs 54 years). A small number of patients received im-
munosuppressant therapy (AZA, CYC or MMF); however,
there was no relationship between immunosuppressant
treatment and cRel dermal staining intensity. Two patients
who received CS in combination with immunosuppres-
sants had reduced levels of cRel staining in the dermis.
Due to the small overall sample size of our patient cohort
(n¼20), the biological/clinical significance of these find-
ings cannot currently be further interpreted. This is a limi-
tation of this study but represents an interesting avenue
to follow in future studies.
cRel activation might represent an earlier step in dis-
ease pathogenesis, by eliciting changes in ECM compos-
ition and creating a fibrogenic microenvironment. The
ECM microenvironment provides cells with physical sup-
port for adhesion and can regulate cell position, cell cycle,
metabolism and differentiated state [52]. Altered ECM
production is not only a consequence but also an active
driver of fibrosis. One hypothesis is that progressive fibro-
sis in the absence of on-going injury occurs in a fibrogenic
niche, e.g. fibrogenic progenitors and fibrogenic progeny
reside in an ECM that is itself fibrogenic [53]. Elevated
cRel in SSc fibroblasts may perpetuate the deposition of
ECM, thus initiating a fibrotic cascade within an injured
microenvironment. This more broadly supports the con-
cept of ‘para-inflammation’ where fibroblasts perpetuate
a self-sustaining feedback loop of matrix deposition
[54].Targeting core fibrogenic signalling pathways, like
cRel, that regulate matrix re-modelling and deposition
could prove beneficial in multi-organ conditions such as
SSc. Previous studies have focussed on the role of ca-
nonical (RelA/p50) signalling in tissue fibrosis using mur-
ine models. Deletion of the p65/RelA subunit is embryonic
lethal [55] and p65/RelA-dependent signalling is critical
for cell survival. Meanwhile, Nfkb1/ mice, which lack
p50/p105, have an accelerated ageing phenotype, driven
by chronic low-level inflammation [56], and p50 signalling
is essential to maintain an appropriate anti-inflammatory
response [57]. Studies by Karin and colleagues utilizing
animal models of disease [58–60] have focussed on the
upstream NF-jB kinase IKKb. Potent IKKb inhibitors,
which blunt canonical NF-jB signalling, resulted in a var-
iety of adverse effects in humans including immunodefi-
ciencies, hepatotoxicity and an increased pre-disposition
to liver and skin malignancies [61].
Rel/ mice develop normally [62] and do not exhibit
signs of gross epidermal defects such as those seen in
Relb/ mice [63]. Deletion of cRel limits inflammation
and fibrosis in murine models of fibrotic disease in mul-
tiple organs and this study has revealed that cRel exerts
discrete functions on fibroblast phenotype. Strategies to
selectively target the cRel subunit of NF-jB have been
successful in graft versus host disease
and melanoma [64, 65] and therapeutic targeting of
cRel using commercially available small molecule inhibi-
tors; IT-603 or IT-609 have not demonstrated adverse
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effects in pre-clinical models[64, 65]. There are currently
no effective anti-fibrotic therapies, and the crucial role of
cRel in controlling ECM production and fibrosis in both,
mouse and human tissues could potentially address this
unmet clinical need.
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